Hypertrophic Cardiomyopathy in Brazil: Advances in Knowledge and Clinical Implications.
作者信息
Guazzelli Danielle Louvet, Avila Mônica Samuel
机构信息
Departamento de Transplante Cardíaco do Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP - Brasil.
出版信息
Arq Bras Cardiol. 2025 Jun 16;122(4):e20250185. doi: 10.36660/abc.20250185. eCollection 2025.
Abstract
摘要
相似文献
1
Hypertrophic Cardiomyopathy in Brazil: Advances in Knowledge and Clinical Implications.巴西的肥厚型心肌病：知识进展与临床意义
Arq Bras Cardiol. 2025 Jun 16;122(4):e20250185. doi: 10.36660/abc.20250185. eCollection 2025.
2
Prevalence, risk factors, and outcomes of QT prolongation in primary and RASopathy-associated hypertrophic cardiomyopathy.原发性及RAS病相关肥厚型心肌病中QT间期延长的患病率、危险因素及结局
Heart Rhythm. 2025 Jun 3. doi: 10.1016/j.hrthm.2025.05.059.
3
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.阿非卡坦治疗有症状的梗阻性肥厚型心肌病：FOREST-HCM研究的48周结果
JACC Heart Fail. 2025 Aug;13(8):102496. doi: 10.1016/j.jchf.2025.03.040. Epub 2025 Jun 19.
4
Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis.儿童肥厚型心肌病性心原性猝死的危险因素：系统评价和荟萃分析。
Eur J Prev Cardiol. 2017 Jul;24(11):1220-1230. doi: 10.1177/2047487317702519. Epub 2017 May 9.
5
[Prevalence of ECG abnormalities in hypertrophic cardiomyopathy: who seeks will find].肥厚型心肌病中心电图异常的患病率：有心者必能发现
Orv Hetil. 2025 Jun 22;166(25):970-981. doi: 10.1556/650.2025.33289.
6
Ischaemic events in hypertrophic cardiomyopathy patients with and without atrial fibrillation: a systematic review and meta-analysis.肥厚型心肌病伴或不伴心房颤动患者的缺血性事件：系统评价和荟萃分析。
J Thromb Thrombolysis. 2023 Jan;55(1):83-91. doi: 10.1007/s11239-022-02713-6. Epub 2022 Oct 3.
7
Durability of mitral valve repair for degenerative mitral valve disease in patients with obstructive hypertrophic cardiomyopathy.梗阻性肥厚型心肌病患者退行性二尖瓣疾病二尖瓣修复的耐久性
J Thorac Cardiovasc Surg. 2025 May 3. doi: 10.1016/j.jtcvs.2025.03.032.
8
A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy.马伐卡坦治疗524例肥厚型心肌病国际队列患者疗效和安全性的系统评价与荟萃分析。
Heart Fail Rev. 2024 Mar;29(2):479-496. doi: 10.1007/s10741-023-10375-6. Epub 2023 Dec 19.
9
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM.玛伐卡坦治疗有症状的非梗阻性肥厚型心肌病：ODYSSEY-HCM研究的设计、原理及基线特征
JACC Heart Fail. 2025 Feb;13(2):358-370. doi: 10.1016/j.jchf.2024.11.013.
10
Exercise Training in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction: A Randomized Clinical Trial.无左心室流出道梗阻的肥厚型心肌病患者的运动训练：一项随机临床试验。
Circulation. 2025 Jan 14;151(2):132-144. doi: 10.1161/CIRCULATIONAHA.124.070064. Epub 2024 Nov 8.
本文引用的文献
1
Clinical and Echocardiographic Particularities of Hypertrophic Cardiomyopathy in a Brazilian Population and its Prognostic Impact.巴西人群肥厚型心肌病的临床和超声心动图特征及其预后影响。
Arq Bras Cardiol. 2025 Apr;122(4):e20240640. doi: 10.36660/abc.20240640.
2
Guidelines on the Diagnosis and Treatment of Hypertrophic Cardiomyopathy - 2024.肥厚型心肌病诊断与治疗指南 - 2024
Arq Bras Cardiol. 2024 Jul 26;121(7):e202400415. doi: 10.36660/abc.20240415.
3
Comparison of mortality and cause of death between adults with and without hypertrophic cardiomyopathy.比较伴有和不伴有肥厚型心肌病的成年人的死亡率和死因。
Sci Rep. 2022 Apr 16;12(1):6386. doi: 10.1038/s41598-022-10389-4.
4
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2020 年 AHA/ACC 肥厚型心肌病患者诊断与治疗指南：概要：美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
J Am Coll Cardiol. 2020 Dec 22;76(25):3022-3055. doi: 10.1016/j.jacc.2020.08.044. Epub 2020 Nov 20.
5
Global Burden of Hypertrophic Cardiomyopathy.肥厚型心肌病的全球负担
JACC Heart Fail. 2018 May;6(5):376-378. doi: 10.1016/j.jchf.2018.03.004.
6
Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy.肥厚型心肌病心力衰竭的临床特征及处理。
JACC Heart Fail. 2018 May;6(5):353-363. doi: 10.1016/j.jchf.2017.09.011. Epub 2018 Apr 11.
7
Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.非梗阻性、易变型和梗阻性肥厚型心肌病患者的临床转归。
J Am Heart Assoc. 2018 Feb 25;7(5):e006657. doi: 10.1161/JAHA.117.006657.
8
Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies.儿童、青少年和青年与当代管理策略相关的肥厚型心肌病的心血管死亡率低。
Circulation. 2016 Jan 5;133(1):62-73. doi: 10.1161/CIRCULATIONAHA.115.017633. Epub 2015 Oct 30.
9
New perspectives on the prevalence of hypertrophic cardiomyopathy.肥厚型心肌病患病率的新视角。
J Am Coll Cardiol. 2015 Mar 31;65(12):1249-1254. doi: 10.1016/j.jacc.2015.01.019.
10
Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance.50年后通过心血管磁共振对肥厚型心肌病表型的再评估
J Am Coll Cardiol. 2009 Jul 14;54(3):220-8. doi: 10.1016/j.jacc.2009.05.006.
Zotero 插件